648 related articles for article (PubMed ID: 12778485)
1. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
2. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.
Ebner C; Schenk S; Najafian N; Siemann U; Steiner R; Fischer GW; Hoffmann K; Szépfalusi Z; Scheiner O; Kraft D
J Immunol; 1995 Feb; 154(4):1932-40. PubMed ID: 7530747
[TBL] [Abstract][Full Text] [Related]
3. Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001.
Smole U; Balazs N; Hoffmann-Sommergruber K; Radauer C; Hafner C; Wallner M; Ferreira F; Grössinger R; de Jong EC; Wagner S; Breiteneder H
Immunobiology; 2010 Nov; 215(11):903-9. PubMed ID: 20005001
[TBL] [Abstract][Full Text] [Related]
4. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a.
Hartl A; Hochreiter R; Stepanoska T; Ferreira F; Thalhamer J
Allergy; 2004 Jan; 59(1):65-73. PubMed ID: 14674936
[TBL] [Abstract][Full Text] [Related]
6. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
7. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
[TBL] [Abstract][Full Text] [Related]
8. Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines.
Reese G; Ballmer-Weber BK; Wangorsch A; Randow S; Vieths S
J Allergy Clin Immunol; 2007 Apr; 119(4):944-51. PubMed ID: 17292955
[TBL] [Abstract][Full Text] [Related]
9. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
[TBL] [Abstract][Full Text] [Related]
10. Bet v 1, the major birch pollen allergen, initiates sensitization to Api g 1, the major allergen in celery: evidence at the T cell level.
Bohle B; Radakovics A; Jahn-Schmid B; Hoffmann-Sommergruber K; Fischer GF; Ebner C
Eur J Immunol; 2003 Dec; 33(12):3303-10. PubMed ID: 14635038
[TBL] [Abstract][Full Text] [Related]
11. Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy.
Repa A; Wild C; Hufnagl K; Winkler B; Bohle B; Pollak A; Wiedermann U
Clin Exp Immunol; 2004 Jul; 137(1):12-8. PubMed ID: 15196238
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
13. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1.
Gieras A; Cejka P; Blatt K; Focke-Tejkl M; Linhart B; Flicker S; Stoecklinger A; Marth K; Drescher A; Thalhamer J; Valent P; Majdic O; Valenta R
J Immunol; 2011 May; 186(9):5333-44. PubMed ID: 21451110
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of Bip 1, a monoclonal antibody that modulates IgE binding to birch pollen allergen, Bet v 1.
Laffer S; Vangelista L; Steinberger P; Kraft D; Pastore A; Valenta R
J Immunol; 1996 Dec; 157(11):4953-62. PubMed ID: 8943401
[TBL] [Abstract][Full Text] [Related]
15. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1.
Vrtala S; Hirtenlehner K; Susani M; Akdis M; Kussebi F; Akdis CA; Blaser K; Hufnagl P; Binder BR; Politou A; Pastore A; Vangelista L; Sperr WR; Semper H; Valent P; Ebner C; Kraft D; Valenta R
FASEB J; 2001 Sep; 15(11):2045-7. PubMed ID: 11511511
[TBL] [Abstract][Full Text] [Related]
16. Engineering, purification and applications of His-tagged recombinant antibody fragments with specificity for the major birch pollen allergen, bet v1.
Flicker S; Laffer S; Steinberger P; Alhani B; Zhu Y; Laukkanen ML; Keinänen K; Kraft D; Valenta R
Biol Chem; 2000 Jan; 381(1):39-47. PubMed ID: 10722049
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune responses to recombinant tree pollen allergens (Bet v I and Bet v II) in mice: construction of a live oral allergy vaccine.
Vrtala S; Grote M; Ferreira F; Susani M; Stocker B; Kraft D; Valenta R
Int Arch Allergy Immunol; 1995; 107(1-3):290-4. PubMed ID: 7613152
[TBL] [Abstract][Full Text] [Related]
18. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
[TBL] [Abstract][Full Text] [Related]
19. Oral exposure to Mal d 1 affects the immune response in patients with birch pollen allergy.
Geroldinger-Simic M; Kinaciyan T; Nagl B; Baumgartner-Durchschlag U; Huber H; Ebner C; Lidholm J; Bartel D; Vieths S; Jahn-Schmid B; Bohle B
J Allergy Clin Immunol; 2013 Jan; 131(1):94-102. PubMed ID: 22921871
[TBL] [Abstract][Full Text] [Related]
20. A non-allergenic Ole e 1-like protein from birch pollen as a tool to design hypoallergenic vaccine candidates.
Marazuela EG; Hajek R; Villalba M; Barber D; Breiteneder H; Rodríguez R; Batanero E
Mol Immunol; 2012 Feb; 50(1-2):83-90. PubMed ID: 22266079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
